X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Divis Laboratories with MYLAN INC. - US - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs MYLAN (US) - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 DIVIS LABORATORIES   MYLAN
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-16
MYLAN
Dec-14
DIVIS LABORATORIES/
MYLAN
5-Yr Chart
Click to enlarge
High Rs2,4843,824-   
Low Rs9182,695-   
Sales per share (Unadj.) Rs142.31,309.1-  
Earnings per share (Unadj.) Rs41.9157.7-  
Cash flow per share (Unadj.) Rs46.3253.8-  
Dividends per share (Unadj.) Rs10.000-  
Dividend yield (eoy) %0.60-  
Book value per share (Unadj.) Rs161.5650.7-  
Shares outstanding (eoy) m265.47378.37-   
Bonus/Rights/Conversions -OI-  
Price / Sales ratio x12.02.5 480.2%   
Avg P/E ratio x40.620.7 196.5%  
P/CF ratio (eoy) x36.712.8 285.9%  
Price / Book Value ratio x10.55.0 210.3%  
Dividend payout %23.90-   
Avg Mkt Cap Rs m451,5251,233,232 36.6%   
No. of employees `0003.725.0 14.8%   
Total wages/salary Rs m3,6490-   
Avg. sales/employee Rs Th10,184.419,812.6 51.4%   
Avg. wages/employee Rs Th984.10-   
Avg. net profit/employee Rs Th2,998.52,386.8 125.6%   
INCOME DATA
Net Sales Rs m37,764495,315 7.6%  
Other income Rs m848-2,887 -29.4%   
Total revenues Rs m38,612492,428 7.8%   
Gross profit Rs m14,138123,187 11.5%  
Depreciation Rs m1,18236,379 3.2%   
Interest Rs m2321,365 0.1%   
Profit before tax Rs m13,78162,556 22.0%   
Minority Interest Rs m0-257 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,6622,631 101.2%   
Profit after tax Rs m11,11959,669 18.6%  
Gross profit margin %37.424.9 150.5%  
Effective tax rate %19.34.2 459.4%   
Net profit margin %29.412.0 244.4%  
BALANCE SHEET DATA
Current assets Rs m30,947435,448 7.1%   
Current liabilities Rs m5,195340,433 1.5%   
Net working cap to sales %68.219.2 355.5%  
Current ratio x6.01.3 465.7%  
Inventory Days Days11778 149.6%  
Debtors Days Days85107 79.4%  
Net fixed assets Rs m17,027114,590 14.9%   
Share capital Rs m53117,516 3.0%   
"Free" reserves Rs m42,3410-   
Net worth Rs m42,877246,220 17.4%   
Long term debt Rs m5367,829 0.0%   
Total assets Rs m49,684991,753 5.0%  
Interest coverage x595.03.9 15,148.0%   
Debt to equity ratio x01.5 0.0%  
Sales to assets ratio x0.80.5 152.2%   
Return on assets %22.48.2 274.5%  
Return on equity %25.924.2 107.0%  
Return on capital %32.213.6 236.3%  
Exports to sales %85.30-   
Imports to sales %22.90-   
Net fx Rs m23,4960-   
CASH FLOW
From Operations Rs m10,37965,110 15.9%  
From Investments Rs m-4,135-51,347 8.1%  
From Financial Activity Rs m-6,241-17,156 36.4%  
Net Cashflow Rs m3-3,394 -0.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 64.16 Rs / USD

Compare DIVIS LABORATORIES With: ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare DIVIS LABORATORIES With: AJANTA PHARMA  SUN PHARMA  ORCHID PHARMA LTD  UNICHEM LAB  AUROBINDO PHARMA  



Today's Market

Global Markets Remain Volatile Ahead of US Growth Concerns(RoundUp)

Benchmark indices in US corrected marginally by 0.8% during the week. Minutes of Federal Reserve's July meeting are out and the situation looks to be in favor of the emerging markets.

Related Views On News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Aug 18, 2017 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES - PLETHICO PHARMA COMPARISON

COMPARE DIVIS LABORATORIES WITH

MARKET STATS